Peptide compounds that reduce the side effects of CB1 receptor agonists

JP2023504765A5Active Publication Date: 2024-11-27UNIV POMPEU FABRA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022520668
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-10-03
Filing Date
2020-10-02
Publication Date
2024-11-27
Estimated Expiration
2040-10-02

AI Technical Summary

Technical Problem

Current cannabinoid receptor agonists, such as THC, effectively alleviate chronic pain but cause severe side effects like memory impairment, anxiety, and social disorders due to activation of CB1 and 5-HT2A receptor heteromers.

Method used

Development of novel synthetic peptides that interfere with CB1 and 5-HT2A receptor heteromers, enhancing hydrolytic stability and crossing the blood-brain barrier to reduce these side effects while maintaining analgesic effects.

Benefits of technology

The peptides efficiently reduce memory impairment and anxiety induced by CB1 receptor agonists, improving the therapeutic index of cannabinoid treatments.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides compounds of formula (I): AA 1 -AA 2 -D-Ile-AA 3 -D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 (I), or pharmaceutically acceptable salts thereof, as well as methods for obtaining them and their therapeutic uses (indications).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to the field of pharmacological therapy using CB1 receptor agonists. [Background technology]

[0002] Nearly one in five Europeans suffers from chronic pain, impacting their work, social, and family lives, resulting in nearly 500 million lost workdays annually and at least 34 billion euros in losses to the European economy. The pain medication market is projected to expand to 100 billion euros by 2019, highlighting the need for novel complementary therapies that can effectively alleviate chronic pain while avoiding undesirable side effects.

[0003] Activation of cannabinoid CB1 receptors (CB1Rs) by CB1 receptor agonists or partial agonists, such as Δ9-tetrahydrocannabinol (THC), the major psychoactive component of cannabis, produces highly interesting pharmacological responses for therapeutic purposes, including the treatment and / or prevention of pain such as severe migraines, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, back pain, knee pain, and pain associated with peripheral or central neuropathic pain; appetite stimulation; antiemetics during chemotherapy in cancer treatment; treatment of glaucoma; treatment of spasticity in patients with multiple sclerosis; and treatment of movement disorders (particularly dyskinesia, Huntington's disease, and Parkinson's disease) (Kandasamy R et al., Eur J Pharmacol. 2018 / 1 / 5;818:271~277; Baron EP et al., Headache Pain. 2018 / 5 / 24;19(1):37; Russo EB et al., Cannabis Cannabinoid Res.2016 July 1;1(1):154~165;Miller S et al., Invest Ophthalmol Vis Sci.2018 December 3;59(15):5904~5911;Escudero-Lara A et al., International Association for the Study of Pain (IASP) 7th World Congress on Pain), Boston, USA, 12~16 September 2018, Abstract ID:471100;La Porta C et al., Pain.2015 October;156(10):2001~12;Maldonado R. et al., Pain.2016 February;157 Addendum 1:S23~32;Engeli S., Handb Exp Pharmacol.2012;(209):357~81;Al-Ghezi ZZ et al., Front Immunol. 2019 / 08 / 21;10:1921; Allen D et al., Clin J Oncol Nurs. 2019 / 2 / 1; 23(1):23~26; Buhmann C et al., J Neural Transm (Vienna) 2019 / 7;126(7):913~924; Valdeolivas S et al., Int J Mol Sci.March 23, 2017; 18(4); see Donovan KA et al., J Adolesc Young Adult Oncol. August 22, 2019 [e-pub ahead of print].

[0004] However, this CB1R activation is associated with various negative effects such as memory impairment, other psychoactive responses such as anxiety alteration, and impairment of social interactions that lead to serious consequences for cannabis users, which is a major drawback for the use of cannabinoids as therapeutic agents.

[0005] Therefore, there is great medical interest in harnessing the beneficial effects of THC and other CB1 receptor agonists.

[0006] 5-HT 2A receptor (5-HT 2A R) deficit mice, behavioral studies have revealed a marked 5-HT 2A R-dependence dissociation in the beneficial antinociceptive effects of THC and its harmful amnestic properties. Specific effects of THC such as memory impairment, anxiety alteration, and social interactions are under the control of 5-HT 2A R, but the acute locomotor inhibitory effect, hypothermic effect, anxiety-provoking effect, and antinociceptive effect of THC have been reported not to be under the control of 5-HT 2A R (Vinals X. et al.; PLoS Biol. July 9, 2015; 13(7):e1002194).

[0007] CB1R and 5-HT 2A R form heteromers that are expressed and functionally active in specific brain regions involved in memory impairment, and that interfering with such heteromer formation leads to a valuable strategy for the selective inhibition of memory impairment and other unwanted side effects caused by exposure to CB1R agonists such as THC (Vinals X. et al.; PLoS Biol. July 9, 2015; 13(7):e1002194).

[0008] In addition, a synthetic peptide having the sequences of transmembrane helices 5 and 6 of the CB1 receptor fused with a cell-permeable peptide can interfere with the receptor heteromerization with 5-HT 2A R in vivo has also been disclosed.

[0009] Now, the inventors have found a novel synthetic peptide that can not only interfere with the heteromers formed by the cannabinoid receptor CB1R and the serotonin receptor 5HT 2A R more efficiently than previously known peptides, but also has higher hydrolytic stability and can efficiently cross the blood-brain barrier.

Summary of the Invention

[0010] In a first aspect, the present invention relates to a compound of formula (I) AA 1 -AA 2 -D-Ile-D-Tyr-AA 3 -D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 (I) (wherein AA 1 represents an amino acid selected from the group consisting of D-tryptophan (D-Trp), D-1-naphthylalanine (D-1-Nal), and D-2-naphthylalanine (D-2-Nal); AA 2 represents an amino acid selected from the group consisting of D-leucine (D-Leu), D-norleucine (D-Nle), and D-phenylalanine (D-Phe); AA 3 represents an amino acid selected from the group consisting of D-methionine (D-Met) and D-norleucine (D-Nle)), or a pharmaceutically acceptable salt thereof.

[0011] In certain embodiments, AA 1 represents D-tryptophan (D-Trp).

[0012] In a particular embodiment, AA 2 This represents D-leucine (D-Leu).

[0013] In a particular embodiment, AA 3 This represents D-tyrosine (D-Tyr).

[0014] In certain embodiments, the compound is D-Trp-D-Leu-D-Ile-D-Tyr-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp or a pharmaceutically acceptable salt thereof It is selected from the group consisting of the following.

[0015] In a second embodiment, the present invention relates to a pharmaceutical composition or veterinary composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Pharmaceuticals in the context of the present invention refers to both human medicine and veterinary medicine.

[0016] In a third aspect, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a pharmaceutical in combination with a CB1 receptor agonist.

[0017] In certain embodiments, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in combination with a CB1 receptor agonist for the treatment or prevention of diseases in animals, including humans, that are easily ameliorated by CB1 receptor agonism.

[0018] In certain embodiments, diseases that are easily improved by CB1 receptor agonism are selected from the group consisting of severe migraines, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, back pain, knee pain, peripheral or central neuropathic pain, appetite-stimulating treatment, antiemetics during chemotherapy, treatment of glaucoma, treatment of spasticity in patients with multiple sclerosis, and pain associated with the treatment of motor disorders (particularly dyskinesia and Parkinson's disease).

[0019] In certain embodiments, treatment and / or prevention may mitigate memory impairment and / or anxiety changes caused by CB1 receptor agonists.

[0020] In a fourth aspect, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in patients treated with a CB1 receptor agonist to mitigate side effects of the CB1 receptor agonist, such as memory impairment, other psychoactive responses such as anxiety changes, and impairments in social interaction. Patients are considered to be mammals, particularly humans, suffering from diseases that are easily improved by administration of a CB1 receptor agonist, in particular pain, severe migraine, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, lower back pain, knee pain, peripheral or central neuropathic pain, appetite stimulation, antiemetics during chemotherapy, treatment of glaucoma, treatment of spasticity in patients with multiple sclerosis, and pain associated with the treatment of motor disorders (in particular, such as dyskinesia and Parkinson's disease).

[0021] In certain embodiments of the third, fourth, fifth, and sixth aspects of the present invention, the CB1 receptor agonist is either a complete agonist or a partial agonist.

[0022] In more specific embodiments of the third, fourth, fifth, and sixth aspects of the present invention, the CB1 receptor agonist is an endogenous cannabinoid produced in mammals, such as 2-arachidonylglycerol (2-AG), 2-arachidonylglyceryl ether (2-AGE, noradin ether), anandamide (N-arachidonoylethanolamine or AEA), N-arachidonoyldopamine, palmitoylethanolamide (PEA); a plant cannabinoid such as 11-hydroxy-Δ8-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, cannabinol, Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol (dronabinol, THC or Δ9-THC), and AM-22 The group consists of synthetic cannabinoids such as 01(1-(5-fluoropentyl)-3-(1-naphthoyl)indole), AM-678(1-pentyl-3-(1-naphthoyl)indole), arachidonyl-2'-chloroethylamide (ACEA), CP55,940([(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)-cyclohexanol]), HU-210, JWH-018(1-pentyl-3-(1-naphthoyl)indole), JWH-073, linoleylethanolamide, levonantradol (CP50,556-1), nabilone, nabiximols, and WIN55,212-2, and in particular, plant-derived cannabinoid THC.

[0023] In other words, the present invention relates to a method for treating or preventing diseases in animals, including humans, that are easily improved by CB1 receptor agonism, by administering a pharmaceutical or veterinary composition comprising a compound of formula (I) to such animals. The aforementioned methods for treating specific diseases and disorders are specific embodiments of the present invention.

[0024] In a fifth aspect, the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with a CB1 receptor agonist to produce a medicament for the treatment or prevention of diseases that are easily improved by CB1 receptor agonism in animals, including humans.

[0025] In certain embodiments, treatment and / or prevention may mitigate memory impairment and / or anxiety changes caused by CB1 receptor agonists.

[0026] In a sixth embodiment, the present invention relates to a method for treating or preventing diseases that are easily improved by CB1 receptor agonism in animals, including humans, by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to an animal in combination with a CB1 receptor agonist.

[0027] In certain embodiments, treatment and / or prevention may mitigate memory impairment and / or anxiety changes caused by CB1 receptor agonists.

[0028] According to a fifth aspect of the present invention, the compound of formula (I) is prepared in the following steps: a) A step of supplying amino acids that form part of a peptide (D-Ala, D-Arg, Gly, D-Ile, D-Leu, D-Lys, D-Met, D-1-Nal, D-2-Nal, D-Nle, D-Phe, D-Trp, D-Tyr, D-Val), b) A step of protecting amino acids D-Lys and D-Trp with Boc, c) A step of protecting the amino acid D-Arg with 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, d) A step of protecting the amino acid D-Thr with t-butyl, e) In an Fmoc-Rink-amide resin, in which DMF is used as a solvent and coupling is carried out with excess Fmoc-amino acids in the presence of excess 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and excess DIEA, a step of assembling amino acids and protective amino acids, f) A step of cleaving the protected side chains of the peptide and the peptide from the resin, preferably using CF3COOH / H2O / 3,6-dioxa-1,8-octanedithiol (DODT) / triisopropylsilane. It can be prepared by a method including [Brief explanation of the drawing]

[0029] [Figure 1] This figure shows an in vitro BBB model. [Figure 2] This is a photograph showing the dotted pattern of peptide fluorescence. [Modes for carrying out the invention]

[0030] As used herein, “compound of formula (I) in combination with a CB1 receptor agonist” means either a fixed combination of compound of formula (I) and a CB1 receptor agonist in a single dose unit form, or a kit of parts comprising a first composition containing compound of formula (I) and a second composition containing a CB1 receptor agonist for combination administration (wherein compound (I) and the CB1 receptor agonist may be administered simultaneously or independently, or separately within a time interval that particularly allows for the mitigation of adverse effects of the CB1 receptor agonist), or any combination thereof.

[0031] As used herein, the term "CB1 receptor agonist" refers to a compound that can activate the CB1 cannabinoid receptor, and ligands such as endogenous cannabinoids produced in mammals, such as 2-arachidonylglycerol (2-AG), 2-arachidonylglyceryl ether (2-AGE, noradin ether), anandamide (N-arachidonylethanolamine or AEA), N-arachidonyldopamine, palmitoylethanolamide (PEA); 11-hydroxy-Δ8-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, cannabinol, Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol (dronabinol, THC or Δ9 This includes plant cannabinoids such as THC, and synthetic cannabinoids such as AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole), AM-678 (1-pentyl-3-(1-naphthoyl)indole), arachidonyl-2'-chloroethylamide (ACEA), CP55,940 ([(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)-cyclohexanol]), HU-210, JWH-018 (1-pentyl-3-(1-naphthoyl)indole), JWH-073, linoleylethanolamide, levonantradol (CP50,556-1), nabilone, nabiximols, and WIN55,212-2.

[0032] In a preferred embodiment, the CB1 cannabinoid receptor agonist is Δ9-tetrahydrocannabinol (THC).

[0033] Where used herein, the expression “pharmaceutically acceptable” refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of sound medical judgment, are suitable for use in contact with the tissues of a subject (e.g., human) without significant toxicity, irritation, allergic reactions, or other problems or complications, and that offer a reasonable benefit / risk ratio. Each carrier, excipient, etc., must also be “acceptable” in the sense that it is compatible with the other components of the pharmaceutical composition. Furthermore, it must be suitable for use in contact with the tissues or organs of humans and animals without excessive toxicity, irritation, allergic reactions, immunogenicity, or other problems or complications, and that offer a reasonable benefit / risk ratio. Suitable carriers, excipients, etc., are listed in standard pharmaceutical texts and include, for example, preservatives, adhesives, humectants, emollients, and antioxidants.

[0034] As used herein, the expression “pharmaceutically acceptable salt” refers to any salt that can provide (directly or indirectly) the compounds described herein for administration to a patient. For example, pharmaceutically acceptable salts of the compounds provided herein are synthesized by conventional chemical methods from parent compounds containing a basic or acidic moiety. Generally, such salts are prepared, for example, by reacting the free acidic or basic form of these compounds with a stoichiometric amount of a suitable base or acid in water, an organic solvent, or a mixture of both. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, 2-propanol, or acetonitrile are preferred. Examples of acid addition salts include mineral acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, and phosphate, and organic acid addition salts such as acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, and p-toluenesulfonate. Examples of alkali addition salts include inorganic salts such as sodium salts, potassium salts, calcium salts, and ammonium salts, and organic alkali salts such as ethylenediamine salts, ethanolamine salts, N,N-dialkyleneethanolamine salts, triethanolamine salts, and basic amino acid salts.

[0035] Throughout this specification and the claims, the word “comprise” and its variations are not intended to exclude other technical features, appendices, components, or processes. Furthermore, the word “comprise” encompasses the case of “consisting of.”

[0036] Peptide synthesis The synthesis of the peptides according to the present invention and the reference example peptides can be carried out by conventional peptide synthesis methods.

[0037] The process described in the following paragraph was actually used to prepare the peptides described in the examples and can be used to prepare any peptide according to the present invention.

[0038] Peptides were assembled on 50 μmol (0.106 g; 0.47 mmol / g) of Fmoc-Rink-amide ChemMatrix resin in a Prelude apparatus (Protein Technologies, Tucson, AZ) running an optimized Fmoc synthesis protocol. Side chain protection was performed with Boc (used to protect D-Lys, Trp, and D-Trp), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (used to protect D-Arg), and t-butyl (used to protect Glu, Ser, Thr, Tyr, and D-Tyr). Double coupling was systematically performed with 5-fold excess Fmoc-amino acids for 5+5 minutes using DMF as the solvent in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 5-fold excess) and DIEA (10-fold excess).

[0039] The deprotection and cleavage cocktail was CF3COOH / H2O / 3,6-dioxa-1,8-octanedithiol (DODT) / triisopropylsilane (94:2.5:2.5:1v / v, 90 min). The synthetic product was isolated by precipitation with cooled diethyl ether, centrifuged at 4°C for 3 × 10 minutes, dissolved in H2O, and lyophilized.

[0040] Peptide analysis and purification The peptides described in this application were purified and analyzed using the following protocol.

[0041] The lyophilized crude peptide was reconstituted by a direct method (H2O acidified with HOAc). The crude peptide was analyzed by HPLC on a Luna C18 column (4.6 × 50 mm, 3 μm, Phenomenex, Torrance, California, USA) in an LC-20AD system (Shimadzu Corporation, Kyoto, Japan). Elution was performed by a linear gradient of solvent B (0.036 v / v% TFA in CH3CN) into solvent A (0.045 v / v% TFA in H2O) over 15 minutes. The peptides were purified by preparative HPLC on a Luna C18 (10×250mm, 10μm, Phenomenex) column in a Shimadzu LC-8A instrument, using a linear gradient of solvent B (0.1v / v% TFA in CH3CN) into solvent A (0.1v / v% TFA in H2O) over 30 minutes at a flow rate of 7 mL / min, while detecting with UV at 220 nm. The fractions with sufficient purity (>95%) obtained by analytical HPLC were pooled, lyophilized, and their identity was re-analyzed by HPLC-MS on a Shimadzu LC-MS2010EV instrument, using a C18 (4.6×150mm column, 3.5μm, Phenomenex) column, eluting with a linear gradient of solvent B (0.08v / v% HCOOH in CH3CN) into solvent A (0.1v / v% TFA in H2O) over 15 minutes at a flow rate of 1 mL / min.

[0042] Abbreviation: The following abbreviations are used in this application: Ala:L-alanine D-Ala: D-alanine D-Arg: D-arginine Glu: L-glutamic acid Gly: Glycine Ile:L-isoleucine D-Ile:D-isoleucine Leu: L-leucine D-Leu: D-Leucine D-Lys: D-lysine Met:L-methionine D-Met: D-methionine D-1-Nal:1-Naphthylalanine((2R)-2-amino-3-naphthalene-1-ylpropanoic acid) D-2-Nal:2-Naphthylalanine((2R)-2-amino-3-naphthalene-2-ylpropanoic acid) D-Nle: D-norleucine Phe:L-phenylalanine D-Phe: D-phenylalanine Ser: L-serine Thr:L-Threonine Trp: L-tryptophan D-Trp: D-tryptophan Tyr:L-tyrosine D-Tyr:D-tyrosine Val:L-Valin D-Val: D-Valin CF: Residues of 5(6)-carboxyfluorescein in the following formula: [ka] -Lys(CF)-NH2: Residues in the following formula: [ka] -D-Lys(CF)-NH2: Residues in the following formula: [ka] Fmoc-Lys(Mtt)-OH [ka] [Examples]

[0043] Reference example 1: The peptide with formula Glu-Thr-Tyr-Leu-Met-Phe-Trp-Ile-Gly-Val-Thr-Ser-Val-Leu-Leu-Leu-Phe-Ile-Val-Tyr-Ala-Tyr-Met-Tyr-Ile-Leu-Trp-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2 (SEQ ID NO: 1-NH2) was prepared using the general synthesis method described above.

[0044] This peptide corresponds to the transmembrane region 5 (TM5) of cannabinoid receptor 1 bound to the cell-permeable peptide sequence Tat(Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg) (SEQ ID NO: 2).

[0045] HPLC:t R 8.10 minutes (a 15-minute straight gradient of 40-90% from B to A). ESI-MS; m / z 1576.45 [M+3H] +3 , 1182.65 [M+4H] +4 , 946.30 [M+5H] +5 , 788.70 [M+6H] +6 , 676.20[M+7H] +7 , 591.75 [M+8H] +8 (Calculated MW value: 4727.76).

[0046] Reference example 2: The peptide with the formula Val-Tyr-Ala-Tyr-Met-Tyr-Ile-Leu-Trp-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 was prepared using the general synthetic method described above.

[0047] This peptide is derived from a partial sequence of amino acids 19-27 of TM5, which is linked to the cell-permeable peptide sequence D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2.

[0048] HPLC:t R 5.24 minutes (15 minutes of straight gradient from B to A with a 30-60% gradient). ESI-MS; m / z: 1023.60 [M+2H] +2 , 682.75 [M+3H] +3 , 511.20 [M+4H] +4 , 411.90 [M+5H] +5 , 340.90 [M+6H] +6 , 292.00 [M+7H] +7(MW calculation value: 2045.52).

[0049] Reference example 3: A peptide with the formula D-Trp-D-Leu-D-Ile-D-Tyr-D-Met-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2, synthesized using the general method described above.

[0050] This peptide originates from a retroenantio version (D-Trp-D-Leu-D-Ile-D-Tyr-D-Met) of a partial sequence of amino acids 23-27 of TM5, which is linked to the cell-permeable peptide sequence D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2. A retroenantio version of a peptide sequence is understood as a new peptide sequence in which all amino acids are replaced by their D-enantiomers, and the order of amino acids in the sequence is reversed.

[0051] HPLC:t R 6.33 minutes (15 minutes of straight gradient from B to A with a 20-60% gradient). ESI-MS; m / z: 1549.70 [M+1H] +1 , 775.45 [M+2H] +2 , 517.35 [M+3H] +3 , 389.95 [M+4H] +4 (MW calculation value: 1548.96).

[0052] Example 1: A peptide with the formula D-Trp-D-Leu-D-Ile-D-Tyr-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2, synthesized using the general method described above.

[0053] This peptide originates from a retroenantiomatic form of a partial sequence of amino acids 19-27 of TM5 (D-Trp-D-Leu-D-Ile-D-Tyr-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val) that has been combined with the cell-permeable peptide sequence D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2. A retroenantiomatic form of a peptide sequence is understood as a new peptide sequence in which all amino acids are replaced by their D-enantiomers, and the order of amino acids in the sequence is reversed.

[0054] HPLC:t R 7.10 minutes (15 minutes of straight gradient from B to A with a 30-60% gradient). ESI-MS; m / z: 1023.90 [M+2H] +2 , 682.70[M+3H] +3 , 512.85 [M+4H] +4 , 409.90 [M+5H] +5 , 340.95 [M+6H] +6 , 293.00 [M+7H] +7 (MW calculation value: 2045.52).

[0055] Example 2: The peptide of Example 1 is labeled by attaching a -Lys(CF)-NH2 residue to its carboxyl terminus.

[0056] Labeling of the peptide's carboxyl terminus (incorporation of 5(6)-carboxyfluorescein) was performed by adding further labeled lysine to the peptide sequence. Fmoc-Lys(Mtt)-OH was used for this purpose.

[0057] In the above compound, the lysine side chain is protected with a methyltrityl (Mtt) protecting group, which can be selectively deprotected in the resin in the presence of 1% TFA (under these conditions, all other side chain protecting groups are stable).

[0058] After condensing the above compound with the carboxy-terminal amino acid of the peptide to be labeled, methyltrityl is removed, and the ε-NH2 group of the "extra" lysine side chain is reacted with the -COOH group of 5(6)-carboxyfluorescein to obtain the labeled peptide. Finally, the carboxy-terminal group is amidated.

[0059] Using this slightly modified peptide, we evaluated its in vitro BBB translocation and intracellular delivery.

[0060] Test method A. Trypsin digestion The stability of the peptide against the action of trypsin was tested by the method described below.

[0061] A 1000 μg / 1000 μL trypsin solution (Thermo Fisher Scientific) was prepared by suspending the lyophilized enzyme in 50 mM ammonium bicarbonate buffer (pH 8.2). A peptide (1 μg / μL) dissolved in the same buffer was incubated with trypsin (peptide:trypsin ratio = 100:1) at 37°C for 24 hours. Samples were collected at various time points, and digestion was stopped by adding 20% ​​(v / v) 0.5% formic acid in H2O. Samples were stored at -20°C until analysis by reverse-phase HPLC-MS. The experiment was performed in two series, and the data were fitted to GraphPad Prism.

[0062] B.bEnd.3 cell culture bEnd.3 brain endothelioma cells (ATCC® CRL-2299®) were incubated in DMEM (Gibco®, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin antibiotic solution for 75 cm³. 2Cells were grown as a monolayer in T flasks. The cells were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO2 (MCO-18AIC(UV), Sanyo Electric, Japan), with the culture medium changed every other day. Once the cells reached confluence, they were collected from the cell culture T flasks using trypsin-EDTA (Gibco®, USA) and used in various assays (cell proliferation, in vitro BBB translocation, and in vitro bimolecular fluorescence complementation).

[0063] C. Cell viability assay The in vitro cytotoxicity of the compounds under evaluation was investigated using the same cell line as the in vitro BBB model, namely bEnd.3 cells, to assess the potential for toxicity. The bEnd.3 cell line was exposed to gradually increasing concentrations of the compound for 24 hours.

[0064] The cytotoxicity of the peptide against bEnd.3 cells was tested using the CellTiter-Blue® cell viability assay, following the manufacturer's instructions as described below.

[0065] This assay is based on the ability of viable cells to reduce resazurin to resorphine, a highly fluorescent metabolite. Non-viable cells cannot produce resorphine. Therefore, this approach can be used to distinguish between metabolic and non-metabolic cells and to indirectly determine the cytotoxicity of various compounds. bEnd.3 cells were seeded at 10,000 cells / 100 μL / well on a 96-well plate (Corning, USA) and incubated for 24 hours. After removing the medium, 100 μL of peptide (in the range of 0.01 to 50 μM) pre-diluted in DMEM medium was added to each well. After 24 hours of incubation, 20 μL of CellTiter-Blue® reagent was added to each well and incubated at 37°C for 3 hours in a humidified atmosphere of 5% CO2. Using an Infinite F200 TECAN plate reader, λ exc =560nm and λ emFluorescence intensity was measured at 590 nm. Standard culture medium and medium containing 1% Triton X-100 were used as positive control (100% cell viability) and negative control (0% cell viability), respectively. Cell viability (%) was calculated using the following equation:

number

[0066] The experiment was conducted on different days using independently grown cell cultures.

[0067] D. In vitro BBB translocation assay bEnd.3 cells were grown to confluence in a culture T flask. The cells were carefully collected using trypsin-EDTA (Gibco®, USA) and seeded at 5,000 cells / well into 1% fibronectin-coated tissue culture inserts (1.0 μm pore clear polyester (PET) membrane) for 24-well plates (BD Falcon, USA). The culture medium was changed every two days for 10 days. After 10 days, the cells were washed twice with 1×PBS and once with phenol red-free DMEM medium (Gibco / Thermo Fisher, USA). The peptide, diluted to a final concentration of 1 μM in phenol red-free DMEM, was then added to the apical side of an in vitro BBB model. Experiments were performed on different days using independently grown cell cultures.

[0068] The translocation of 5(6)-carboxyfluorescein-labeled peptides is determined by fluorescence emission.

[0069] The in vitro BBB model consists of a Transwell system with an insert in which bEnd.3 cells proliferate in two separate chambers (see Figure 1). The insert, i.e., the apical side, corresponds to the blood side of the blood-brain barrier, while the basolateral side (lower chamber) corresponds to the brain side of the blood-brain barrier.

[0070] To investigate the peptide's translocation ability, 1 μM of the 5(6)-carboxyfluorescein-labeled peptide under evaluation was added to the apical side of the in vitro BBB model described above. After 24 hours of incubation, apical and basal volumes were collected, and fluorescence in these samples was measured separately using a plate reader. The intracellular translocation percentage was obtained as the difference between total fluorescence and the sum of apical and basal fluorescence.

[0071] After 24 hours of incubation, samples were collected from the apical and basal ends and analyzed. Fluorescence was measured using an infinite F200 TECAN plate reader. The translocation percentage (%) was calculated using the following equation:

number

[0072] F i F is the recovered fluorescence intensity. 細胞 F is the fluorescence intensity recovered from cells that did not undergo peptide incubation. ペプチド This represents the fluorescence intensity of the total peptide initially added to the Transwell apex.

[0073] The integrity of the endothelial barrier is assessed by the permeability of fluorescently labeled dextran (FD)(FD4) with a molecular weight of 4 kDa. Information about the integrity of the blood-brain barrier can be obtained by measuring the clearance of the fluorescent probe from the apical end in the presence or absence of the labeled peptide.

[0074] E. CB by bimolecular fluorescence complementation 1 R and 5-HT 2A In vitro determination of the ability to destroy heteromers with R Vinals * X, Moreno *E, Lanfumey L, Cordomi A, Pastor A, de La Torre R, Gasperini P, Navarro G, Howell LA, Pardo L, Lluis C, Canela EI, McCormick * PJ, Maldonado * R, Robledo * The method described in P. "Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors." PLoS Biology, 13(7):e1002194 (2015) is used with some modifications as described herein, and involves the interaction of CB1R and 5-HT 2A We assessed the in vitro ability of the peptide to disrupt the heteromer with R.

[0075] Expression vector YFP Venus semi-truncated protein (5-HT) fused to the target receptor 2A To obtain R-cYFP, CB1R-nYFP, 5-HT 2A R was subcloned in-frame into the restriction enzyme site of pcDNA3.1-cVenus, which contains the sequence encoding amino acid residues 156–238 of the YFP Venus protein. Furthermore, CB1R was subcloned in-frame into the restriction enzyme site of pcDNA3.1-nVenus, which contains the sequence encoding amino acid residues 1–155 of the YFP Venus protein.

[0076] The expression of the constructs was examined by confocal microscopy, and the functionality of the receptor fusion protein was tested by ERK1 / 2 phosphorylation.

[0077] Cell culture and transient transfection Human embryonic kidney (HEK-293T) cells obtained from ATCC were grown in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 2 mM L-glutamine, 100 μg / ml sodium pyruvate, 100 U / ml penicillin / streptomycin, MEM non-essential amino acid solution (1 / 100), and 5% (v / v) heat-inactivated fetal bovine serum (FBS) (all supplements were from Invitrogen, Paisley, Scotland, UK). The cells were maintained at 37°C in a 5% CO2 atmosphere.

[0078] Fluorescence complementation assay Cells proliferating in 6-welldish were fused with CB1R fused with the YFP Venus N-terminal fragment (n-YFP) and 5-HT fused with the YFP Venus C-terminal fragment (c-YFP). 2A The cDNA encoding R was transiently transfected using the PEI (polyethyleneimine, Sigma) method. Cells were incubated with the corresponding cDNA in serum starvation medium along with PEI and 150 mM NaCl for 4 hours. After 4 hours, the medium was replaced with fresh complete medium.

[0079] After 48 hours, cells were either treated with the indicated TAT-peptide (4 μM) or left untreated at 37°C for 4 hours. To quantify complementary YFP Venus expression, cells were rapidly washed twice consecutively with HBSS containing 10 mM glucose, detached, and resuspended in the same buffer. To control cell count, sample protein concentrations were measured using a Bradford assay kit (Bio-Rad, Munich, Germany) with a bovine serum albumin dilution as the standard. 20 μg of protein was distributed into a 96-well microplate (black plate with a clear bottom, Porvair, Kings Lynn, UK), and fluorescence emission was recorded at 530 nm after excitation at 500 nm using a Mithras LB940 (Berthold Technologies, Bart Wildbad, Germany). Protein fluorescence was determined as the fluorescence of the sample minus the fluorescence (baseline) of untransfected cells. 5-HT2A Cells expressing R-cVenus and nVenus, or cells expressing CB1R-nVenus and cVenus, showed similar fluorescence levels to untransfected cells.

[0080] Example 3 (Trypsin stability of the compound from Example 1) HPLC analysis of the compound in Example 1 yielded the results summarized in Table 1 during incubation with trypsin provided as described in Method A above.

[0081] [Table 1] This demonstrates that the compound in Example 1 is highly resistant to trypsin digestion, with over 80% of the starting peptide remaining undegraded after 24 hours.

[0082] Example 4 (Cytotoxicity of the compound from Example 1) The cytotoxicity of the compound in Example 1 was evaluated as provided in Method B. above, and the results are summarized in Table 2 below.

[0083] [Table 2]

[0084] Based on the above results, EC 50 The value is higher than 50 μM. This experiment shows that the compound in Example 1 does not have significant toxicity.

[0085] Example 5 (Translocation of the compound from Example 2) The translocation of the compound of Example 2 (the 5(6)-carboxyfluorescein-labeled peptide of Example 1) was evaluated as provided by Method D. described above.

[0086] A total of 1 μM of the peptide from Example 2 (the 5(6)-carboxyfluorescein-labeled peptide from Example 1) was initially added to the apical side. After 24 hours of incubation, the relative amounts of the peptide at the apical side, intracellular translocation, and basolateral side were quantified. The amounts at the apical and basolateral sides were normalized by the initial total amount of labeled peptide added to the apex and expressed as a percentage of the recovered fluorescence dose. The amount of peptide translocated into the cell is the difference between the initial added amount and the amounts at the apical and basolateral sides. The results are shown in Table 3 below:

[0087] [Table 3]

[0088] The data obtained demonstrates that the peptide from Example 2 (the peptide from Example 1 labeled with 5(6)-carboxyfluorescein) can translocate the blood-brain barrier (BBB) ​​up to 43.39±2.703% in 24 hours, with an intracellular retention rate of 19.98±7.324%.

[0089] The integrity of the endothelial barrier was evaluated as described in Method D. Clearance of the fluorescent probe (fluorescently labeled dextran (FD)(FD4) with a molecular weight of 4 kDa) from the apical side was negligible both in the presence and absence of the labeled peptide, demonstrating the absence of both cell barrier fenestration and paracellular leakage.

[0090] Example 6 (CB by bimolecular fluorescence complementarity) 1 R and 5-HT 2A (In vitro testing of the ability to destroy heteromers with R) CB1R and 5-HT 2A The ability of the compound in Example 1 to disrupt the heteromer with R was evaluated by bimolecular fluorescence complementarity based on Method E described above, and the results are summarized in Table 4.

[0091] [Table 4]

[0092] Example 7 Evaluation of intracellular peptide transport by confocal microscopy bEnd.3 cells were seeded at 50,000 cells / 200 μL for 24 hours on ibiTreat-coated 8-well μ-slides (Ibidi, Germany). The cells were then carefully washed twice with 1× PBS and once with culture medium, and incubated with a final concentration of 10 μM labeled peptide for 2 hours. After 2 hours, the cells were again washed twice with 1× PBS and once with culture medium, and the nuclei and membranes were stained with Hoescht 33342 (ThermoFisher, USA) and CellsMask® Deep Red (ThermoFisher, USA), respectively. The nuclear and membrane dyes were added to the cells in a 0.5× working solution at a final concentration of 5 μg / mL at 37°C for 10 minutes. Finally, the cells were washed twice with 1× PBS and imaged.

[0093] Images were acquired using a confocal scanning Zeiss LSM880 microscope (Carl Zeiss, Germany) equipped with an αPlan-Apochromat × 100 oil immersion objective lens (numerical aperture 1.46). Hoesch 33342 (Sigma-Aldrich, Spain) and CellMask® Deep Red plasma membrane dye (ThermoFisher, USA) were excited using a diode 405-30 and a HeNe 633 laser. The peptide from Example 2 (the peptide from Example 1 labeled with 5(6)-carbovolecein-Lys) was excited using a 488 nm line from an argon laser. In normal confocal mode, 0.6x zoom images were recorded at a resolution of 1024 × 1024. ZEN software was used for image acquisition. Fiji software was used for image processing. At least 12 images in total were acquired in three separate repetitions. To confirm the intracellular translocation of the peptide from Example 2 (i.e., the peptide from Example 1 labeled with 5(6)-carbovolecein-Lys), bEnd.3 cells were incubated with 10 μM of the peptide at 37°C for 2 hours and examined using a confocal microscope.

[0094] A dotted pattern of peptide fluorescence was observed, indicating the presence of the peptide in the vesicle fraction after intracellular translocation. This is shown in Figure 2.

[0095] Example 8: In vivo determination of the effect of peptides on memory (novel object recognition test) The effects of peptides on memory were evaluated using the method described in "Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. 'Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling.' Nature Neuroscience, 12(9):1152~8 (2009)," with some modifications as described herein. The results are summarized in Table 5 below.

[0096] On day 1 (habituation), mice were habituated to a V-maze for 9 minutes to perform a task. On day 2 (training), the mice were returned to the V-maze for 9 minutes, presented with two identical objects, and the time spent by the mice exploring each object was recorded. After 24 hours, the mice were placed back into the V-maze for 9 minutes (test), one of the familiar objects was replaced with a new object, and the total time spent exploring each of the two objects (new and familiar) was calculated. Object exploration was defined as the direction of the mouse's nose being less than 2 cm from the object. The discrimination index was calculated by dividing the difference in time spent exploring the new or familiar object by the total time spent exploring the two objects. Since normal mice spend more time exploring new objects than familiar ones, a higher discrimination index is thought to indicate better memory retention for familiar objects.

[0097] Mice were treated with the test peptide in a vehicle (physiological saline + 2% DMSO) at a dose of 20 mg of the peptide per kg of body weight, or with the vehicle alone, by intravenous administration (IV) immediately after training. Meanwhile, 3 mg of THC per kg of mouse weight, dissolved in an IP vehicle (5 v / v% ethanol, 5 v / v% Cremophor-EL, and 90 v / v% physiological saline) or an IP vehicle, was administered by intraperitoneal injection (IP) 30 minutes after the peptide administration.

[0098] [Table 5]

[0099] The results summarized in the table above demonstrate that co-administration of the compound in Example 1 reverses the harmful effects of THC on memory.

[0100] Example 9: In vivo evaluation of the analgesic effect of peptides (hot plate test) “Monory K,Blaudzun H,Massa F,Kaiser N,Lemberger T,Schutz G,Wotjak CT,Lutz B * Marsicano G * The analgesic effect of the peptide was evaluated using the method described in "Genetic Dissection of Behavioural and Autonomic Effects of D9-tetrahydrocannabinol in Mice," PLOS Biology, 5(10):e269, 2007, with some modifications as described herein. The results are summarized in Table 6 below.

[0101] [Table 6]

[0102] THC-induced analgesia was measured using a Hot / Cold Plate Test (Bioseb, USA) by intraperitoneal injection (IP) of THC dissolved in an IP vehicle (5 v / v% ethanol, 5 v / v% Cremophor-EL, and 90 v / v% saline) or by intravenous injection of the vehicle alone (saline + 2% DMSO) 60 minutes after the first injection, and by intravenous injection 90 minutes after the first injection of the test peptide in an IV vehicle or the vehicle alone. The plate was heated to 52 ± 0.5°C, and the time (in seconds) until the mouse exhibited a foot-licking and jumping response on the plate was recorded (foot-licking and jumping latency). A cutoff time of 240 seconds was used to prevent tissue damage.

[0103] The co-administration of the compound from Example 1 with THC makes it possible to achieve a substantial analgesic effect.

[0104] List of References Non-patent documents cited in the specification 1. Vinals X. et al; PLoS Biol. 2015 Jul 9;13(7):e1002194 2. Kandasamy R, Dawson CT, Craft RM, Morgan MM. Anti-migraine effect of Δ9-tetrahydrocannabinol in the female rat. Eur J Pharmacol. 2018 Jan 5;818:271-277. doi: 10.1016 / j.ejphar.2017.10.054. Epub 2017 Oct 28. 3. Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. Headache Pain. 2018 May 24;19(1):37. doi: 10.1186 / s10194-018-0862-2. 4. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-165. doi: 10.1089 / can.2016.0009. eCollection 2016. 5. Miller S, Daily L, Leishman E, Bradshaw H, Straiker A. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5904-5911. doi: 10.1167 / iovs.18-24838. 6. Escudero-Lara A, Argerich J, Cabanero D, Maldonado R. Δ9-tetrahydrocannabinol (THC) alleviates pelvic hypersensitivity in a mouse model of endometriosis. IASP (International Association for the Study of Pain) 7th World Congress on Pain. Boston, USA. 12-16 September 2018, Abstract ID: 471100. 7. La Porta C, Bura SA, Llorente-Onaindia J, Pastor A, Navarrete F, Garcia-Gutierrez MS, De la Torre R, Manzanares J, Monfort J, Maldonado R. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain. 2015 Oct;156(10):2001-12. 8. Maldonado R, Banos JE, Cabanero D. The endocannabinoid system and neuropathic pain. Pain. 2016 Feb;157 Suppl 1:S23-32. 9. Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol. 2012;(209):357-81. doi: 10.1007 / 978-3-642-24716-3_17. 10. Al-Ghezi ZZ, Miranda K, Nagarkatti M, Nagarkatti PS . Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways. Front Immunol. 2019 Aug 21;10:1921. 11. Allen D. Dronabinol Therapy: Central Nervous System Adverse Events in Adults With Primary Brain Tumors. Clin J Oncol Nurs. 2019 Feb 1;23(1):23-26. 12. Buhmann C, Mainka T, Ebersbach G, Gandor F. Evidence for the use of cannabinoids in Parkinson's disease. J Neural Transm (Vienna). 2019 Jul;126(7):913-924. 13. Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernandez-Ruiz J. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6 / 2 Mice, an Experimental Model of Huntington's Disease. Int J Mol Sci. 2017 Mar 23;18(4). 14. Donovan KA, Oberoi-Jassal R, Chang YD, Rajasekhara S, Haas MF, Randich AL, Portman DG. Cannabis Use in Young Adult Cancer Patients. J Adolesc Young Adult Oncol. 2019 Aug 22. doi: 10.1089 / jayao.2019.0039. [Epub ahead of print]

Claims

1. Compounds of formula (I): AA 1 -AA 2 -D-Ile-D-Tyr-AA 3 -D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH 2 (I) (In the formula, A.A. 1 represents an amino acid selected from the group consisting of D-tryptophan (D-Trp), D-1-naphthylalanine (D-1-Nal) and D-2-naphthylalanine (D-2-Nal); A.A. 2 represents an amino acid selected from the group consisting of D-leucine (D-Leu), D-norleucine (D-Nle) and D-phenylalanine (D-Phe); A.A. 3 represents an amino acid selected from the group consisting of D-methionine (D-Met), D-tyrosine (D-Tyr), and D-norleucine (D-Nle); or a pharma- ceutically acceptable salt thereof.

2. A.A. 1 The compound of claim 1, wherein represents D-tryptophan (D-Trp).

3. A.A. 2 The compound according to any one of claims 1 to 2, wherein represents D-leucine (D-Leu).

4. D-Trp-D-Leu-D-Ile-D-Tyr-D-Met-D-Tyr-D-Ala-D-Tyr- D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH 3 or a pharma- ceutically acceptable salt thereof The compound according to any one of claims 1 to 3, selected from the group consisting of:

5. A pharmaceutical or veterinary composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 4.

6. 2-Arachidonoylglycerol (2-AG), 2-arachidonylglycerylether (2-AGE, noladinether), anandamide (N-arachidonoylethanolamine or AEA), N-arachidonoyldopamine, palmitoylethanolamide (PEA); 11-hydroxy-Δ8-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, cannabinol, Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol (dronabinol, THC or Δ9-THC), AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole ), AM-678 (1-pentyl-3-(1-naphthoyl)indole), arachidonyl-2'-chloroethylamide (ACEA), CP 55,940 ([(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)-cyclohexanol]), HU-210, JWH-018 (1-pentyl-3-(1-naphthoyl)indole), JWH-073, linoleylethanolamide, levonantradol (CP 50,556-1), nabilone, nabiximols and WIN 55,212-2, and mixtures thereof. 1 In combination with a receptor agonist, CB1 expression in animals, including humans, 1 6. The pharmaceutical composition of claim 5, for use in the treatment or prevention of a disease or condition susceptible to amelioration by agonism of the receptor.

7. Said CB 1 7. A pharmaceutical composition according to claim 6, wherein the disease or condition susceptible to improvement by agonism of the receptor is selected from the group consisting of severe migraine, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, back pain, knee pain, pain associated with peripheral or central neuropathic pain, for appetite stimulant treatment, as an antiemetic during chemotherapy, for the treatment of glaucoma, in the treatment of spasticity in multiple sclerosis patients, and for the treatment or prevention of movement disorders, such as in particular dyskinesia and Parkinson's disease.

8. 2-Arachidonoylglycerol (2-AG), 2-arachidonylglycerylether (2-AGE, noladinether), anandamide (N-arachidonoylethanolamine or AEA), N-arachidonoyldopamine, palmitoylethanolamide (PEA); 11-hydroxy-Δ8-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, cannabinol, Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol (dronabinol, THC or Δ9-THC), AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole ), AM-678 (1-pentyl-3-(1-naphthoyl)indole), arachidonyl-2'-chloroethylamide (ACEA), CP 55,940 ([(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)-cyclohexanol]), HU-210, JWH-018 (1-pentyl-3-(1-naphthoyl)indole), JWH-073, linoleylethanolamide, levonantradol (CP 50,556-1), nabilone, nabiximols and WIN 55,212-2, and mixtures thereof. 1 In combination with a receptor agonist, CB 1 6. The pharmaceutical composition according to claim 5, which is used for the treatment (alleviation) of memory impairment and / or anxiety changes induced by receptor agonists.

9. Said CB 1 8. The pharmaceutical composition of claim 6 or 7, wherein the disease or condition amenable to amelioration by agonism of the receptor is pain.

10. The pharmaceutical composition of claim 9, wherein the pain is chronic pain.

11. 11. The pharmaceutical composition of claim 7, 9 or 10, wherein the pain is associated with severe migraine headaches, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, back pain, knee pain, and peripheral or central neuropathic pain.

12. Said CB 1 7. The pharmaceutical composition of claim 6, wherein the treatment of a disease or condition susceptible to improvement by agonism of the receptor is the treatment of a disease or condition selected from the group consisting of anorexia, emesis induced by chemotherapy in the treatment of cancer, glaucoma, spasticity in multiple sclerosis patients, and movement disorders (especially Huntington's disease, dyskinesia and Parkinson's disease).

13. CB in animals, including humans 1 CB1 for the manufacture of a medicament for the treatment or prevention of a disease susceptible to amelioration by agonism of a receptor. 1 5. Use of a compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, in combination with a receptor agonist.

14. Said CB 1 14. The use according to claim 13, wherein the disease or condition susceptible to improvement by agonism of the receptor is selected from the group consisting of severe migraine, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, back pain, knee pain, pain associated with peripheral or central neuropathic pain, in appetite stimulant treatment, as an antiemetic during chemotherapy, for the treatment of glaucoma, in the treatment of spasticity in multiple sclerosis patients, and in the treatment of movement disorders (such as dyskinesias and Parkinson's disease, in particular).

15. C.B. 1 Use of a compound according to any one of claims 1 to 4 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for alleviating memory impairment and / or anxiety changes caused by a receptor agonist.

16. Said CB 1 15. The use according to claim 13 or 14, wherein the disease or condition amenable to amelioration by agonism of the receptor is pain.

17. 17. The use according to claim 16, wherein the pain is chronic pain.

18. 18. The use according to claim 13, 16 or 17, wherein the pain is associated with severe migraine headaches, osteoarthritis, endometriosis, rheumatoid arthritis, fibromyalgia, back pain, knee pain, and peripheral or central neuropathic pain.

19. Said CB 1 14. The use according to claim 13, wherein the treatment of a disease or condition susceptible to improvement by agonism of the receptor is the treatment of a disease or condition selected from the group consisting of anorexia, vomiting induced by chemotherapy in the treatment of cancer, glaucoma, spasticity in multiple sclerosis patients, and movement disorders, such as Huntington's disease, dyskinesia and Parkinson's disease, among others.

20. The treatment or prevention is 1 Use according to any one of claims 13, 14, 16 to 19, which is also capable of alleviating memory impairment and / or anxiety changes caused by receptor agonists.